Company: BIAF
Filing Date: 2025-04-22
Form Type: 424B3
Source: 0001641172-25-005598
Chunk: 57

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-22
Form: 424B3
Chunk 57
---
 In-licensing patents covering our diagnostic tests and therapeutic product candidates in all countries
throughout the world may similarly be prohibitively expensive, if such opportunities are available at all. And in-licensing or filing,
prosecuting, and defending patents even in only those jurisdictions in which we develop or commercialize our diagnostic tests and therapeutic
product candidates may be prohibitively expensive or impractical. Competitors may use our and our licensors’ technologies in jurisdictions
where we have not obtained patent protection or licensed patents to develop their own diagnostic tests and therapeutic products and further
may export otherwise infringing products to territories where we and our licensors have patent protection, but where enforcement is not
as strong as that in the U.S. or Europe. These diagnostic tests and products may compete with our diagnostic tests and therapeutic product
candidates, and our or our licensors’ patents or other intellectual property rights may not be effective or sufficient to prevent
them from competing.

The laws of some jurisdictions do not protect intellectual
property rights to the same extent as the laws or regulations in the U.S. and Europe, and many companies have encountered significant
difficulties in protecting and defending proprietary rights in such jurisdictions. Moreover, the legal systems of certain countries, particularly
certain developing countries, do not favor the enforcement of patents, trade secrets, or other forms of intellectual property, particularly
those relating to biotechnology tests and products, which could make it difficult for us to prevent competitors in some jurisdictions
from marketing competing tests and products in violation of our proprietary rights generally. Proceedings to enforce our patent rights
in foreign jurisdictions, whether or not successful, are likely to result in substantial costs and divert our efforts and attention from
other aspects of our business, and additionally could put at risk our or our licensors’ patents of being invalidated or interpreted
narrowly, could increase the risk of our or our licensors’ patent applications not issuing, or could provoke third parties to assert
claims against us. We may not prevail in any lawsuits that we initiate, while damages or other remedies may be awarded to the adverse
party, which may be commercially significant. If we prevail, damages or other remedies awarded to us, if any, may not be commercially
meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant
commercial advantage from the intellectual property that we develop or license. Furthermore, while we intend to protect our intellectual
property rights in our expected significant markets, we cannot ensure that we will be